1. Gleich GJ. The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol. 1990; 85:422–36.
Article
2. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000; 105:651–63.
Article
3. Sanderson CJ. Interleukin-5: an eosinophil growth and activation factor. Dev Biol Stand. 1988; 69:23–9.
4. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26:239–57.
Article
5. Allen RT, Hunter WJ 3rd, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 1997; 37:215–28.
Article
6. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, et al. Human ICE/CED-3 protease nomenclature. Cell. 1996; 87:171.
Article
7. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood. 1995; 86:1437–43.
Article
8. Walsh GM, Williamson ML, Symon FA, Willars GB, Wardlaw AJ. Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colonystimulating factor. Blood. 1996; 87:2815–21.
Article
9. Blaylock MG, Sexton DW, Walsh GM. Ligation of CD45 and the isoforms CD45RA and CD45RB accelerates the rate of constitutive apoptosis in human eosinophils. J Allergy Clin Immunol. 1999; 104:1244–50.
Article
10. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992; 68:421–7.
Article
11. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985; 66:848–58.
Article
12. Jung W, Krueger S, Renner C, Gause A, Sahin U, Trümper L, et al. Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol. 1994; 31:1329–34.
Article
13. Masuda M, Ishida C, Arai Y, Okamura T, Ohsawa M, Shimakage M, et al. Dual action of CD30 antigen: anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells. Int J Hematol. 1998; 67:257–65.
14. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000; 96:4307–12.
Article
15. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994; 83:2045–56.
Article
16. Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol. 2000; 165:5105–11.
Article
17. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood. 1996; 88:3299–305.
Article
18. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999; 90:157–64.
Article
19. Berro AI, Perry GA, Agrawal DK. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004; 173:2174–83.
Article
20. Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004; 172:2186–93.
Article
21. Hansel TT, De Vries IJ, Iff T, Rihs S, Wand-zilak M, Betz S, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods. 1991; 145:105–10.
Article
22. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol. 1997; 158:3902–8.
23. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000; 356:2144–8.
24. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003; 167:199–204.
Article
25. Matsumoto K, Terakawa M, Fukuda S, Saito H. Rapid and strong induction of apoptosis in human eosinophils by anti-CD30 mAb-coated microspheres and phagocytosis by macrophages. Int Arch Allergy Immunol. 2007; 143(Suppl 1):60–7.
Article
26. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996; 271:12852–8.
Article
27. Horie R, Aizawa S, Nagai M, Ito K, Higashihara M, Ishida T, et al. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int Immunol. 1998; 10:203–10.
Article
28. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003; 14:193–209.
Article
29. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem. 1998; 273:2926–30.
Article
30. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997; 90:405–13.
Article
31. Matsumoto K, Terakawa M, Fukuda S, Saito H. Analysis of signal transduction pathways involved in anti-CD30 mAb-induced human eosinophil apoptosis. Int Arch Allergy Immunol. 2010; 152(Suppl 1):2–8.
Article